P19 NPR-B Receptor Antagonist 

Chemokine Receptor Antagonist Development

This chapter describes assays that focus on the characterization of compounds identified in high-�throughput screening campaigns, and the subsequent medicinal chemistry programs. They cover methods to determine potency

Developing a Photoreactive Antagonist

approach for developing small molecules that, upon irradiation with light, may be used to rapidly inactivate targeted proteins expressed on the surfaces of cells. Highlighted is ANQX, a photoreactive AMPA receptor antagonist developed to irreversibly

p19cl6细胞

constitutively overexpressing the BMP antagonist noggin, did not differentiate into cardiomyocytes. Cooverexpression of Smad1, a ligand-specific Smad, and Smad4, a common Smad, restored the ability of P19CL6noggin to differentiate into cardiomyocytes